Development and study of specific Kir channel inhibitors

特异性Kir通道抑制剂的开发与研究

基本信息

  • 批准号:
    7186629
  • 负责人:
  • 金额:
    $ 31.18万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-04-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term goals of our research are to develop inhibitors specifically targeting individual subtypes of ion channels, to determine inhibitor-channel interaction mechanisms, and to use the inhibitors to examine channel physiology and demonstrate certain therapeutic concepts. Since inward-rectifier K+ (Kir) channels play many vital physiological roles and represent increasingly important therapeutic targets, subtype-specific Kir channel inhibitors are experimentally and therapeutically valuable. The studies proposed below will be carried out with a combined approach of electrophysiology, biochemistry, and molecular biology. Previously, we discovered that a 21-residue honey bee toxin, tertiapin (TPN), inhibits renal Kir1.1 and cardiac Kir3.1/3.4 channels with nanomolar affinity. In Aim#1, we will create inhibitors specific for Kir1.1 or Kir3.1/3.4. Our preliminary studies have not only identified the channel sequence that will allow the selective targeting of various Kir subtypes but also established the prototype for such a subtype-specific inhibitor. The resulting specific inhibitors can be used in future studies to help prove the concept of new classes of medicine for treating certain cardiac diseases. Additionally, we found that piperazine - a very safe and inexpensive anthelmintic which has been shown to be anti-arrhythmic in some animal preparations - selectively inhibits strongly rectifying Kir channels such as Kir 2.1. The selectivity and safety of piperazine make it (or its derivatives) a promising candidate agent for treating certain cardiac arrhythmias. Because of this potential therapeutic value we will, in Aim#2, investigate the mechanisms by which piperazine interacts with the channel through a combination of energetic and structural studies. Furthermore, as the first step toward proving the concept, we will demonstrate that certain blocking properties of piperazine can be exploited for treating a form of short QT syndrome caused by a mutation in Kir2.1. The outcome of the proposed studies will significantly enhance our ability to decipher the physiological functions of Kir channels in a given cell type or tissue, and help in the development of effective therapeutic agents.
描述(由申请人提供):我们研究的长期目标是开发特异性靶向单个离子通道亚型的抑制剂,以确定通道-通道相互作用机制,并使用抑制剂检查通道生理学并证明某些治疗概念。由于内向整流K+(Kir)通道发挥许多重要的生理作用,并且代表越来越重要的治疗靶点,因此亚型特异性Kir通道抑制剂具有实验和治疗价值。将采用电生理学、生物化学和分子生物学相结合的方法进行以下拟议的研究。以前,我们发现,21个残基的蜜蜂毒素,tertiapin(TPN),抑制肾Kir1.1和心脏Kir3.1/3.4通道与纳摩尔亲和力。在目标1中,我们将创建Kir1.1或Kir3.1/3.4特异性抑制剂。我们的初步研究不仅确定了允许选择性靶向各种Kir亚型的通道序列,而且还建立了这种亚型特异性抑制剂的原型。由此产生的特异性抑制剂可用于未来的研究,以帮助证明治疗某些心脏疾病的新药物类别的概念。此外,我们发现哌嗪-一种非常安全和廉价的驱虫剂,在一些动物制剂中显示出抗蠕虫-选择性地抑制强烈的整流Kir通道,如Kir 2.1。哌嗪的选择性和安全性使其(或其衍生物)成为治疗某些心律失常的有希望的候选药物。由于这种潜在的治疗价值,我们将在目标#2中通过能量和结构研究的组合来研究哌嗪与通道相互作用的机制。此外,作为证明这一概念的第一步,我们将证明哌嗪的某些阻断特性可用于治疗Kir2.1突变引起的短QT综合征。拟议研究的结果将显着提高我们破译给定细胞类型或组织中Kir通道生理功能的能力,并有助于开发有效的治疗药物。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ZHE LU其他文献

ZHE LU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ZHE LU', 18)}}的其他基金

Kinetic mechanisms of amino acid transporters
氨基酸转运蛋白的动力学机制
  • 批准号:
    10434789
  • 财政年份:
    2020
  • 资助金额:
    $ 31.18万
  • 项目类别:
Kinetic mechanisms of amino acid transporters
氨基酸转运蛋白的动力学机制
  • 批准号:
    10655437
  • 财政年份:
    2020
  • 资助金额:
    $ 31.18万
  • 项目类别:
Kinetic mechanisms of amino acid transporters
氨基酸转运蛋白的动力学机制
  • 批准号:
    10027946
  • 财政年份:
    2020
  • 资助金额:
    $ 31.18万
  • 项目类别:
Kinetic mechanisms of amino acid transporters
氨基酸转运蛋白的动力学机制
  • 批准号:
    10187562
  • 财政年份:
    2020
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development of novel means to stimulate Ca2+-dependent exocytotic secretion
开发刺激 Ca2 依赖性胞吐分泌的新方法
  • 批准号:
    9155329
  • 财政年份:
    2016
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development and study of specific Kir channel inhibitors
特异性Kir通道抑制剂的开发与研究
  • 批准号:
    7092755
  • 财政年份:
    2001
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
  • 批准号:
    6727515
  • 财政年份:
    2001
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development and study of specific Kir channel inhibitors
特异性Kir通道抑制剂的开发与研究
  • 批准号:
    7586210
  • 财政年份:
    2001
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
  • 批准号:
    6520330
  • 财政年份:
    2001
  • 资助金额:
    $ 31.18万
  • 项目类别:
Development /use of peptidic inhibitors for Kir channels
Kir 通道肽抑制剂的开发/使用
  • 批准号:
    6326870
  • 财政年份:
    2001
  • 资助金额:
    $ 31.18万
  • 项目类别:

相似海外基金

RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
  • 批准号:
    2327346
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Standard Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
  • 批准号:
    2312555
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Standard Grant
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
  • 批准号:
    BB/Z514391/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Training Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
  • 批准号:
    ES/Z502595/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Fellowship
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
  • 批准号:
    ES/Z000149/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Research Grant
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
  • 批准号:
    23K24936
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
  • 批准号:
    2901648
  • 财政年份:
    2024
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Studentship
ERI: Developing a Trust-supporting Design Framework with Affect for Human-AI Collaboration
ERI:开发一个支持信任的设计框架,影响人类与人工智能的协作
  • 批准号:
    2301846
  • 财政年份:
    2023
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Standard Grant
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
  • 批准号:
    488039
  • 财政年份:
    2023
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Operating Grants
How motor impairments due to neurodegenerative diseases affect masticatory movements
神经退行性疾病引起的运动障碍如何影响咀嚼运动
  • 批准号:
    23K16076
  • 财政年份:
    2023
  • 资助金额:
    $ 31.18万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了